Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 study of ALPHA-1062 nasal spray formulation to treat traumatic brain injury

Next Previous
X
Search
Trial Profile

A Phase 2 study of ALPHA-1062 nasal spray formulation to treat traumatic brain injury

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benzgalantamine (Primary)
  • Indications Traumatic brain injuries
  • Focus Therapeutic Use

    • Most Recent Events

    • 22 Aug 2023 According to an Alpha Cognition media release, the company expects Alpha Seven Therapeutics will initiate the additional toxicity direct manufacturing and manufacturing work, which would be anticipated to complete in 2H, 2024. Alpha Seven Therapeutics would then be in the position to file an IND for ALPHA-1062IN. First patient enrolment expected in during 2H 2023 and in 2024 Last patient enrolled followed by initial Phase 2 clinical results.
    • 25 Aug 2022 According to an Alpha Cognition media release, the company plans to request an FDA meeting to discuss the clinical development of intranasal ALPHA-1062 for the treatment of traumatic brain injury (TBI). It is anticipated that this meeting will take place in Q4 2022.
    • 07 Oct 2021 According to an Alpha Cognition media release, the company is planning to initiate this trial in fall with top-line data read-out in late Q1 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top